In Regulatory First, Myeloma Drug Approved Based on MRD Negativity.
原始摘要（英文原文）· Original abstract
The FDA has approved iberdomide for multiple myeloma based on minimal residual disease negativity, marking a first for the disease. The drug also ushers in a new generation of targeted protein degraders, with several more potent cereblon E3 ligase modulators already in clinical development.